FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ... Read more
FREE Market Signals & Ideas!
You will never miss our latest news, trading ideas, podcasts, and market signals.
You have successfully joined our subscriber list.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.